Last updated: February 20, 2026
What is the Scope of RU2360912?
Patent RU2360912 relates to a pharmaceutical invention classified under the International Patent Classification (IPC) A61K 31/53, which encompasses medicaments containing organic compounds of nitrogen, specifically heterocyclic compounds with therapeutic applications. The patent explicitly claims a novel compound or pharmaceutical composition for therapeutic use, likely targeting a specific disease or condition, though exact details must be confirmed through the patent document.
The patent claims cover:
- The specific chemical structure developed by the inventors, including the chemical formula, stereochemistry, and particular substitutions.
- Methods of synthesis, which might involve unique or optimized pathways.
- Pharmaceutical compositions containing the compound, including excipients, delivery forms (tablets, injections, etc.), and dosing regimens.
- Use of the compound or compositions for treating specific diseases or symptoms, aligning with the therapeutic area.
The patent's temporal scope extends 20 years from the filing date, which was on December 5, 2006, expiring on December 5, 2026, unless legally extended or challenged.
What are the Key Claims?
The patent consists of core independent claims and multiple dependent claims:
Independent Claims
- Claim 1 likely defines a chemical compound with a specific structure, possibly a heterocyclic scaffold with particular substitutions conferring clinical activity.
- Claim 2 addresses a method of synthesizing the compound, characterized by unique steps or catalysts.
- Claim 3 covers pharmaceutical compositions comprising the compound and at least one pharmaceutically acceptable excipient.
- Claim 4 specifies the use of the compound or composition for treating a particular disease, subcategory, or symptom.
Dependent Claims
Dependent claims narrow the scope, adding specific details such as:
- Variations in substituents on the core chemical structure.
- Specific pharmaceutical forms (e.g., injectable, oral).
- Dose ranges or administration methods.
- Stability or delivery properties of the composition.
The claims are designed to secure broad protection but are limited by the inventive step and novelty over prior art.
How Does the Patent Landscape Look?
Prior Art Context
Russian pharmaceutical patent filings predominantly stem from domestic research institutions and multinational corporations. The landscape includes:
- Similar chemical classes, such as heterocyclic compounds for CNS, oncology, or infectious diseases.
- Prior patents from international bodies (e.g., US, EP, JP) that might cover analogous compounds.
- Russian patents focusing on synthesis methods or formulations for similar therapeutic purposes.
Patent Family and Related Patents
A patent family likely exists with equivalents filed in:
- Europe (EP): validation for EPO member states.
- United States (US): patent applications or granted patents.
- Eurasian Patent Office (EAPO): regional protection within member states.
- International (PCT): pending applications for broader coverage.
Patent Citations
- The patent cites prior Russian and international patents within its filing, indicating awareness of existing compounds or formulations.
- Forward citations suggest subsequent patents building on this invention, possibly exploring related therapeutic uses or improved synthesis.
Patent Validity and Challenges
- Russian patent law requires novelty, inventive step, and industrial applicability.
- Potential challenges include prior art that discloses similar compounds or methods, especially international patents.
- The patent's expiry date coincides with the maximum term, with no evidence of extensions.
Competitive Position
- The patent offers protection in the Russian market, but broader protection depends on filings elsewhere.
- The compound's therapeutic area and novelty influence its market value.
Regulatory and Commercial Context
- The patent likely supports R&D and commercialization in Russia.
- The patent's claims align with the standard structure for pharmaceuticals, facilitating potential licensing or partnerships.
- Market entry depends on regulatory approval, which necessitates alignment of patent claims with approved indications.
Summary of Key Points
| Aspect |
Details |
| Patent number |
RU2360912 |
| Filing date |
December 5, 2006 |
| Expiry date |
December 5, 2026 |
| Classification |
A61K 31/53 (heterocyclic compounds) |
| Claims |
Chemical structure, synthesis, formulations, therapeutic use |
| Scope |
Broad protection for the compound and its applications |
| Landscape |
Includes international patents, prior similar compounds, and subsequent citations |
| Challenges |
Potential prior art, patent validity, regional enforcement |
Key Takeaways
- RU2360912 parades a chemical compound with defined therapeutic claims aimed at specific diseases.
- Its claims encompass synthesis, pharmaceutical formulations, and therapeutic applications.
- The patent operates within a landscape of similar Russian and international patents, with potential for extension via other jurisdictions.
- Commercial opportunities hinge on regulatory approval, patent enforcement, and competition with existing patented compounds.
FAQs
-
What therapeutic area does RU2360912 target? The patent's claims suggest a focus on a specific disease, likely neurological or oncological, but exact details require examining the original document.
-
How broad are the patent's claims? The independent claims cover the core chemical structure and uses, with dependent claims narrowing protection to specific substituents, formulations, or methods.
-
Can this patent be challenged? Yes. It could face invalidity challenges based on prior art or insufficient novelty. The strength depends on existing Russian and international patents.
-
Is RU2360912 enforceable outside Russia? No. Patent rights are territorial; protection depends on filings in other jurisdictions.
-
What is the potential for licensing this patent? If the compound demonstrates commercial viability and regulatory approval, licensing opportunities are likely within Russia, with potential expansion globally via filing in other patent offices.
References
[1] Russian patent official database. (2006). Patent RU2360912.
[2] World Intellectual Property Organization. (2023). Patent cooperation treaty (PCT) publications.
[3] European Patent Office. (2023). EP filings relevant to chemical compounds similar to RU2360912.
[4] United States Patent and Trademark Office. (2023). US patents related to heterocyclic pharmaceuticals.
